

13 February 2025

**Hammerson plc (the "Company")**

**TRANSACTION IN OWN SHARES**

The Company announces that, in accordance with the terms of its share buyback programme announced on 16 October 2024 (the "**Share Buyback Programme**"), the Company has purchased the following number of its ordinary shares of 5 pence each from Morgan Stanley & Co. International plc. Such purchase was effected pursuant to instructions issued by the Company on 16 October 2024.

Date of purchase:	12 February 2025
Number of ordinary shares purchased:	61,686
Highest price paid per share (pence):	294.40
Lowest price paid per share (pence):	289.20
Volume weighted average price paid per share (pence):	291.79

The Company will cancel the purchased shares.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as incorporated into and implemented under English law (including by virtue of the European Union (Withdrawal) Act 2018), a full breakdown of the individual trades made by Morgan Stanley & Co. International plc on behalf of the Company as part of the Share Buyback Programme is attached to this document and can be accessed through the link provided below.

[http://www.rns-pdf.londonstockexchange.com/rns/9152W\\_1-2025-2-12.pdf](http://www.rns-pdf.londonstockexchange.com/rns/9152W_1-2025-2-12.pdf)

Since 16 October 2024 pursuant to the Share Buyback Programme, the Company has purchased 8,963,122 ordinary shares.

**This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.**

Contact:

**Josh Warren**

Director of Strategy, Commercial Finance and Investor Relations

Tel: +44 20 7887 1053

[josh.warren@hammerson.com](mailto:josh.warren@hammerson.com)

**Richard Crowle**

Senior Assistant Company Secretary

Tel: +44 20 7887 1000

[www.hammerson.com](http://www.hammerson.com)

[Richard.crowle@hammerson.com](mailto:Richard.crowle@hammerson.com)

*The announcement above has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSGPUUPPUPAGMP